Aims and Scope
Leukemia is a peer-reviewed medical journal published by the Nature Publishing Group. It was established in 1987 by Nicole Muller-Bérat Killman and Sven-Aage Killman, and is currently edited by Professors Andreas Hochhaus and Robert Peter Gale. The journal covers research on all aspects of leukemia and has a 2019 impact factor of 8.665.
Key Metrics
17.6
CiteScore
CiteScore
CiteScore measures average citations received per document published in the serial.
0.01 - 0.05
Eigenfactor
Eigenfactor
Eigenfactor Score measures the number of times articles from the journal published in the past five years have been cited. This does not include self citations.
10 - 15
Impact Factor
Impact Factor
Impact factor of a journal is calculated by dividing the number of current year citations to the source items published in that journal during the previous two years.
211
H index
H-Index
Journal's h-index reflects the collective citation impact of the authors publishing in the journal. The h-index is defined as the maximum value of h such that the given journal has published at least h papers that have each been cited at least h times.
0.91
5-Year SI
5-year SI
- 0.95 2-year SI
- 0.87 Lifetime SI
Scite Index
Scite Index
scite Index is the ratio of citations supporting research which is published in the journal to sum of citations either supporting or contrasting the research published in the journal for the same time period. Minimum 100 supporting citations required.
Q1
Oncology
SJR
- Q1 Oncology
- Q1 Hematology
- Q1 Cancer Research
- Q1 Anesthesiology and Pain Medicine
SJR
SJR
SCImago Journal Rank measures weighted citations received by the serial. Citation weighting depends on subject field and prestige (SJR) of the citing serial.
2.69
SNIP
SNIP
Source Normalized Impact per Paper measures actual citations received relative to citations expected for the serial’s subject field.
4 Mo
Time to Publish
Time to Publish
Based on turnaround time from submission to publication for papers (articles & reviews) published in 2022 and for journals with a sample of more than 10 papers.
Topics Covered
- Germline
- Overall survival
- Minimal residual disease
- Antibody response
- Bone marrow
- Myeloid leukemia
- Poor prognosis
- Hematopoietic stem cell transplantation
- Cytarabine
- Lenalidomide
- Tyrosine kinase
- B-cell lymphoma
- Hematopoietic stem cell
- Nilotinib
- Serum protein
- B-cell acute lymphoblastic leukemia
- Genome
- Conventional treatment
- Rituximab
- Hematologic Neoplasms
Journal Specifications
| Overview | |
| Publisher | SPRINGERNATURE |
| Language | English |
| Frequency | Monthly |
| General Details | |
| Language | English |
| Frequency | Monthly |
| Publication Start Year | 1987 |
| Publisher URL | Visit website |
| Website URL | Visit website |
Planning to publish in Leukemia ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Looking for the right journals to submit your mansucript?
Upload your manuscript and get a submission readiness score and other journal recommendations.
Check my PaperRecently Published Papers
-
Full paper
Autophagy degrades immunogenic endogenous retroelements induced by 5-azacytidine in acute myeloid leukemia
- 16 Apr 24
- Leukemia
-
Full paper
Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF
- 12 Mar 24
- Leukemia
-
Full paper
Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis: A retrospective analysis of the DRST and GREM registries
- 6 Mar 24
- Leukemia
-
Full paper
Long-term outcomes after upfront second-generation tyrosine kinase inhibitors for chronic myeloid leukemia: managing intolerance and resistance
- 29 Feb 24
- Leukemia
-
Full paper
Correction: Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib – interim results from the DAstop2 trial
- 28 Feb 24
- Leukemia
-
Full paper
Germline variants in patients developing second malignant neoplasms after therapy for pediatric acute lymphoblastic leukemia—a case-control study
- 27 Feb 24
- Leukemia
Scite analysis
Powered by scite_
10.8k articles received 441.9k citations see all
- 20,294 Supporting
- 411,659 Mentioning
- 2,886 Contrasting
Editorial notices
- 7 Retractions
- 0 Withdrawals
- 114 Corrections
- 219 Errata
- 0 Expression of Concern
Time To Publish
Time to Publish
Based on turnaround time from submission to publication for papers (articles & reviews) published in 2022 and for journals with a sample of more than 10 papers.
Time to Publish
Based on turnaround time from submission to publication for papers (articles & reviews) published in 2022 and for journals with a sample of more than 10 papers.
% of papers by time taken from submission to publication
0 to 3 months
30%
4 to 6 months
46%
7 to 9 months
18%
Above 9 months
6%
Did you find this useful?
Thank you for your feedback.
FAQs
How long has Leukemia been actively publishing?
Leukemia has been in operation since 1987 till date.
What is the publishing frequency of Leukemia ?
Leukemia published with a Monthly frequency.
How many articles did Leukemia publish last years ?
In 2023, Leukemia published 166 articles.
What is the eISSN & pISSN for Leukemia ?
For Leukemia,eISSN is 1476-5551 and pISSN is0887-6924.
What is Citescore for Leukemia ?
Citescore for Leukemia is 17.6.
What is H index for Leukemia ?
H index for Leukemia is 211.
What is SNIP score for Leukemia ?
SNIP score for Leukemia is 2.69.
What is the SJR for Leukemia ?
SJR for Leukemia is Q1.
Who is the publisher of Leukemia ?
SPRINGERNATURE is the publisher of Leukemia.